{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:31:03Z","timestamp":1786966263721,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06630-8","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:16:00Z","timestamp":1786965360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peroneal electrical transcutaneous neuromodulation (peroneal eTNM\u00ae) for the treatment of OAB\u2014review on principles, mode of action and clinical outcomes"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-5926","authenticated-orcid":false,"given":"Jan","family":"Krhut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Rychl\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"6630_CR1","first-page":"71","volume":"8","author":"RS Eapen","year":"2016","unstructured":"Eapen RS, Radomski SB (2016) Review of the epidemiology of overactive bladder. Res Rep Urol 8:71\u201376","journal-title":"Res Rep Urol"},{"key":"6630_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12955-015-0274-9","volume":"13","author":"KS Lee","year":"2015","unstructured":"Lee KS, Choo MS, Seo JT et al (2015) Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes 13:89","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 11","key":"6630_CR3","first-page":"S580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6(Suppl 11):S580\u2013S590","journal-title":"Am J Manag Care"},{"key":"6630_CR4","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.cont.2024.101694","volume":"11","author":"MA Perrouin-Verbe","year":"2024","unstructured":"Perrouin-Verbe MA, Van Kerrebroeck PEV (2024) The future of neuromodulation for functional pelvic problems. Continence 11:101694","journal-title":"Continence"},{"key":"6630_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11934-017-0711-x","volume":"18","author":"K Jaqua","year":"2017","unstructured":"Jaqua K, Powell CR (2017) Where are we headed with neuromodulation for overactive bladder? Curr Urol Rep 18:59","journal-title":"Curr Urol Rep"},{"key":"6630_CR6","doi-asserted-by":"crossref","unstructured":"Krhut J, Peter L, Rejchrt M, Slovak M, Skugarevska B, Zvara P (2021) Peroneal electric transcutaneous neuromodulation (eTNM\u00ae): a novel method for the treatment of the overactive bladder. J Healthc Eng 2021:4016346","DOI":"10.1155\/2021\/4016346"},{"key":"6630_CR7","doi-asserted-by":"publisher","first-page":"103337","DOI":"10.1016\/j.autneu.2025.103337","volume":"261","author":"PL Dequirez","year":"2025","unstructured":"Dequirez PL, De Wachter S, Biardeau X (2025) Sacral neuromodulation for low urinary tract dysfunction: overview and mechanisms of action. Auton Neurosci 261:103337","journal-title":"Auton Neurosci"},{"key":"6630_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41585-024-00967-8","volume":"22","author":"J Krhut","year":"2025","unstructured":"Krhut J, Kobber\u00f8 H, Kanaan R, Fode M, Poulsen M, Zvara P (2025) The mechanism of action of neuromodulation in the treatment of overactive bladder. Nat Rev Urol 22:414\u2013426","journal-title":"Nat Rev Urol"},{"key":"6630_CR9","doi-asserted-by":"crossref","unstructured":"Al-Danakh A, Safi M, Alradhi M et al (2022) Posterior tibial nerve stimulation for overactive bladder: mechanism, classification, and management outlines. Parkinsons Dis 2022:2700227","DOI":"10.1155\/2022\/2700227"},{"key":"6630_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.neurom.2022.11.016","volume":"27","author":"J Krhut","year":"2024","unstructured":"Krhut J, Tint\u011bra J, Rejchrt M et al (2024) Brain response induced by peroneal electrical transcutaneous neuromodulation for overactive bladder treatment as detected by functional magnetic resonance imaging. Neuromodulation 27:353\u2013359","journal-title":"Neuromodulation"},{"key":"6630_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrurol.2015.266","volume":"12","author":"D Griffiths","year":"2015","unstructured":"Griffiths D (2015) Neural control of micturition in humans: a working model. Nat Rev Urol 12:695\u2013705","journal-title":"Nat Rev Urol"},{"key":"6630_CR12","doi-asserted-by":"publisher","first-page":"914963","DOI":"10.3389\/fphys.2022.914963","volume":"13","author":"D Pang","year":"2022","unstructured":"Pang D, Gao Y, Liao L (2022) Functional brain imaging and central control of the bladder in health and disease. Front Physiol 13:914963","journal-title":"Front Physiol"},{"key":"6630_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/nau.25197","volume":"42","author":"J Krhut","year":"2023","unstructured":"Krhut J, Tint\u011bra J, Rejchrt M et al (2023) Differences between brain responses to peroneal electrical transcutaneous neuromodulation and transcutaneous tibial nerve stimulation. Neurourol Urodyn 42:1352\u20131361","journal-title":"Neurourol Urodyn"},{"key":"6630_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000522570","volume":"106","author":"J Krhut","year":"2022","unstructured":"Krhut J, Rejchrt M, Skugarevska B, Grepl M, Zvara P (2022) Peroneal electrical transcutaneous neuromodulation as a new treatment for patients with overactive bladder: an initial clinical experience. Urol Int 106:658\u2013663","journal-title":"Urol Int"},{"key":"6630_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00192-022-05359-3","volume":"34","author":"J Krhut","year":"2023","unstructured":"Krhut J, Rejchrt M, Slovak M, Dvorak RV, Grepl M, Zvara P (2023) Peroneal electrical transcutaneous neuromodulation in the home treatment of refractory overactive bladder. Int Urogynecol J 34:1253\u20131260","journal-title":"Int Urogynecol J"},{"key":"6630_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/JU.0000000000003141","volume":"209","author":"J Krhut","year":"2023","unstructured":"Krhut J, Rejchrt M, Slovak M et al (2023) Prospective randomized multicenter trial of peroneal electrical transcutaneous neuromodulation vs solifenacin in treatment-na\u00efve patients with overactive bladder. J Urol 209:734\u2013741","journal-title":"J Urol"},{"key":"6630_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5173\/ceju.2024.0261","volume":"78","author":"J Krhut","year":"2025","unstructured":"Krhut J, Rejchrt M, Slov\u00e1k M, Peter L, Zvara P (2025) Peroneal electric transcutaneous neuromodulation versus solifenacin in the treatment of the overactive bladder wet. Cent Eur J Urol 78:323\u2013330","journal-title":"Cent Eur J Urol"},{"key":"6630_CR18","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00345-023-04394-z","volume":"41","author":"M Rejchrt","year":"2023","unstructured":"Rejchrt M, Krhut J, G\u00e4rtner M, Blok BFM, Zvara P (2023) Effect duration of the initial course of peroneal electrical transcutaneous neuromodulation in patients with overactive bladder. World J Urol 41:1629\u20131634","journal-title":"World J Urol"},{"key":"6630_CR19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","volume":"75","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet B, Mironska E, Chapple C et al (2019) A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol 75:988\u20131000","journal-title":"Eur Urol"},{"key":"6630_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/nau.22544","volume":"34","author":"S Siegel","year":"2015","unstructured":"Siegel S, Noblett K, Mangel J et al (2015) Results of a prospective randomized multicenter study evaluating sacral neuromodulation with InterStim therapy. Neurourol Urodyn 34:224\u2013230","journal-title":"Neurourol Urodyn"},{"key":"6630_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/17434440.2022.2032655","volume":"19","author":"S Tilborghs","year":"2022","unstructured":"Tilborghs S, De Wachter S (2022) Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. Expert Rev Med Devices 19:161\u2013187","journal-title":"Expert Rev Med Devices"},{"key":"6630_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/JU.0000000000000656","volume":"203","author":"HS Harvie","year":"2020","unstructured":"Harvie HS, Amundsen CL, Neuwahl SJ et al (2020) Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence. J Urol 203:969\u2013977","journal-title":"J Urol"},{"key":"6630_CR23","doi-asserted-by":"publisher","first-page":"1014291","DOI":"10.3389\/fmed.2022.1014291","volume":"9","author":"P Liu","year":"2022","unstructured":"Liu P, Li Y, Shi B, Zhang Q, Guo H (2022) Comparison of different types of therapy for overactive bladder: a systematic review and network meta-analysis. Front Med (Lausanne) 9:1014291","journal-title":"Front Med (Lausanne)"},{"key":"6630_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.eururo.2017.11.002","volume":"73","author":"M Tutolo","year":"2018","unstructured":"Tutolo M, Ammirati E, Heesakkers J et al (2018) Efficacy and safety of sacral and percutaneous tibial neuromodulation. Eur Urol 73:406\u2013418","journal-title":"Eur Urol"},{"key":"6630_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.neurom.2022.06.004","volume":"26","author":"J Huang","year":"2023","unstructured":"Huang J, Fan Y, Zhao K et al (2023) Comparative efficacy of neuromodulation technologies for overactive bladder in adults. Neuromodulation 26:1535\u20131548","journal-title":"Neuromodulation"},{"key":"6630_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.neurom.2023.09.002","volume":"27","author":"S Parodi","year":"2024","unstructured":"Parodi S, Kendall HJ, Terrone C, Heesakkers JPFA (2024) What is in the pipeline on investigational neuromodulation techniques for lower urinary tract dysfunction: a narrative review. Neuromodulation 27:267\u2013272","journal-title":"Neuromodulation"},{"key":"6630_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12325-024-03019-0","volume":"42","author":"CL Amundsen","year":"2025","unstructured":"Amundsen CL, Sutherland SE, Kielb SJ, Dmochowski RR (2025) Sacral and implantable tibial neuromodulation for the management of overactive bladder: a systematic review and meta-analysis. Adv Ther 42:10\u201335","journal-title":"Adv Ther"},{"key":"6630_CR28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/nau.25477","volume":"43","author":"JPFA Heesakkers","year":"2024","unstructured":"Heesakkers JPFA, Toozs-Hobson P, Sutherland SE et al (2024) A prospective study to assess the effectiveness and safety of the BlueWind system in the treatment of patients diagnosed with urgency urinary incontinence. Neurourol Urodyn 43:1491\u20131503","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 1","key":"6630_CR29","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.5489\/cuaj.4337","volume":"11","author":"S Ramsay","year":"2017","unstructured":"Ramsay S, Bolduc S (2017) Overactive bladder in children. Can Urol Assoc J 11(Suppl 1):S74\u2013S79","journal-title":"Can Urol Assoc J"},{"key":"6630_CR30","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00192-021-04909-5","volume":"32","author":"V Duong","year":"2021","unstructured":"Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C (2021) A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J 32:2693\u20132702","journal-title":"Int Urogynecol J"},{"key":"6630_CR31","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/nau.25037","volume":"41","author":"J Zillioux","year":"2022","unstructured":"Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB (2022) SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn 41:1928\u20131933","journal-title":"Neurourol Urodyn"},{"key":"6630_CR32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/0269215518780974","volume":"32","author":"N Hare","year":"2018","unstructured":"Hare N, Georgopoulos P, Philips KE et al (2018) Improvement in overactive bladder symptoms in patients using functional electrical stimulation of the common peroneal nerve for walking. Clin Rehabil 32:1357\u20131362","journal-title":"Clin Rehabil"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06630-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06630-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06630-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:16:02Z","timestamp":1786965362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06630-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6630"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06630-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JK: consultant for Coloplast, Medtronic, Astellas and Stimvia; TR and PZ: nothing to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"578"}}